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Abstract
Background: We conducted a review of the diagnostic accuracy of clinical examination for the
diagnosis of cirrhosis. The objectives were: to identify studies assessing the accuracy of clinical
examination in the detection of cirrhosis; to summarize the diagnostic accuracy of reported
physical examination findings; and to define the effects of study characteristics on estimates of
diagnostic accuracy.
Methods: Studies were identified through electronic literature search of MEDLINE (1966 to
2000), search of bibliographic references, and contact with authors. Studies that evaluated indicants
from physical examination of patients with known or suspected liver disease undergoing liver
biopsy were included. Qualitative data on study characteristics were extracted. Two-by-two tables
of presence or absence of physical findings for patients with and without cirrhosis were created
from study data. Data for physical findings reported in each study were combined using Summary
Receiver Operating Characteristic (SROC) curves or random effects modeling, as appropriate.
Results: Twelve studies met inclusion criteria, including a total of 1895 patients, ranging in age
from 3 to 90 years. Most studies were conducted in referral populations with elevated
aminotransferase levels. Ten physical signs were reported in three or more studies and ten signs
in only a single study. Signs for which there was more study data were associated with high
specificity (range 75–98%), but low sensitivity (range 15–68%) for histologically-proven cirrhosis.
Conclusions: Physical findings are generally of low sensitivity for the diagnosis of cirrhosis, and
signs with higher specificity represent decompensated disease. Most studies have been undertaken
in highly selected populations.
Background
Cirrhosis is a pathologic condition characterized by fibro-
sis of the liver parenchyma and evidence of regenerative
activity [1]. It is a common pathologic end-point for a
number of processes, including damage by toxins, meta-
bolic diseases, or virus-induced hepatitis, autoimmune
hepatitis, passive congestion secondary to heart failure, or
infection with parasites. The epidemiology of cirrhosis is
linked to both alcohol consumption [2–5] and the preva-
lence of hepatitis B and hepatitis C virus infections [5].
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Worldwide, cirrhosis is the cause of approximately 850
thousand deaths per year [6]. The majority of these are in
developing nations, where viral hepatitis is the main un-
derlying cause of cirrhosis. In developed nations, alcohol
is a major cause of cirrhosis, but the early mortality risk at-
tributed to alcohol in younger age groups (15–45 years
old) is somewhat offset by the proposed beneficial effect
of alcohol on cardiovascular mortality [5].
The diagnosis of cirrhosis has both prognostic and thera-
peutic implications [7]. The life expectancies for persons
diagnosed with cirrhosis are significantly reduced [8–11]
compared with age and sex-matched controls, with the ex-
ception of certain pathological subtypes [12]. The likeli-
hood of variceal bleeding is reported to be greatest within
the first two years of diagnosis [13]. Owing to the high
mortality risk associated with variceal hemorrhage, prima-
ry prophylaxis against a first bleed becomes an important
therapeutic intervention [9]. There are several other thera-
pies that are clinically useful for patients with established
cirrhosis [14,15], as well as therapies for specific causes of
liver disease, such as viral hepatitis [16].
Cirrhosis may be suspected from physical examination
findings [17], with imaging studies frequently supporting
the diagnosis. It is known though, that imaging studies are
limited in their ability to make a definite assessment in
patients with diffuse infiltrative conditions of the liver
[18]. Ultrasound, the most widely used modality, is nei-
ther sensitive nor specific for the diagnosis of cirrhosis
[19]. Estimates of the sensitivity range from 57 to 92%
and specificity between 39 and 81% [20,21]. Despite cer-
tain limitations, liver biopsy remains the gold standard
for diagnosis. This procedure is not without risk. There is
a small mortality risk of around 0.015 percent, together
with the resulting discomfort and other non-fatal compli-
cations [13,22]. The patchy or regional nature of hepatic
changes means that percutaneous liver biopsies may miss
the diagnosis of cirrhosis in 24 percent of patients with
the condition [23].
Given the invasive nature of the diagnostic standard, there
has been interest in whether non-invasive diagnosis of cir-
rhosis might be possible [13,24]. Physical examination is
a diagnostic tool available to every clinician. This study
was conducted to review the published literature on clini-
cal examination of patients with known or suspected liver
disease and identify the validity and generalizability of
primary studies that distinguished those with cirrhosis
from those without. A summary of diagnostic test per-
formance for elements of the physical examination was
derived using meta-analytic methods for diagnostic stud-
ies. Where possible, effects of study characteristics on
summary estimates were determined by subgroup analy-
sis.
Methods
Study identification
Two online searches of the National Library of Medicine
MEDLINE database were performed using the PubMed
search engine. The searches covered the years 1966–2000.
The last search was completed on August 15, 2000. The
first search utilized the Clinical Queries tool, using the
term "cirrhosis", and the options "diagnosis" and "specif-
icity". A second search combined medical subject head-
ings (MeSH) "Signs and Symptoms", "Physical
Examination", and "Medical History Taking", linked by
OR terms, with a text word search for "cirrhosis", through
an AND term. The resulting set was further limited by the
term "human", and by excluding reviews, editorials, or
letters. The titles of the resulting citations were scanned.
Abstracts of potentially relevant articles were then re-
trieved. If the article appeared likely to satisfy inclusion
criteria from information available in the abstract, or if no
abstract was available, the full text article was evaluated.
Additional articles were sought by scanning bibliogra-
phies in standard reference textbooks, proceedings of
meetings or conferences on cirrhosis or liver disease, the
reference sections of selected articles or review articles on
liver disease, cirrhosis, or physical examination, or other
potentially relevant chapters in books. The authors of pri-
mary studies identified through literature searches were
contacted by letter or by email or both, seeking data not
presented in the published study, and to enquire about
knowledge of unpublished or additional studies.
Study selection criteria
Articles were included if they: evaluated patients with
known or suspected liver disease or cirrhosis; evaluated
items obtained by physical examination; described liver
biopsy results; and provided data sufficient to calculate
sensitivity and specificity of elements of the clinical exam-
ination in the detection of cirrhosis. Studies that evaluated
only biochemical or radiological examinations were ex-
cluded.
Validity assessment
The validity of included articles was evaluated for the fol-
lowing four criteria [25,26] by one author (GdB): inde-
pendent, blind comparison against a reference standard of
diagnosis; evaluation in an appropriate spectrum of pa-
tients; the reference standard was applied, regardless of di-
agnostic test (in this case, physical examination) result;
and the reference standard was measured prior to starting
any interventions based on the examination findings.
The reference standard for diagnosis of cirrhosis was his-
tological evidence of irreversible chronic injury to liver pa-
renchyma with extensive fibrosis and formation of
regenerative nodules. This definition conforms to the def-
inition used in the study from which the sensitivity of per-BMC Medical Informatics and Decision Making 2001, 1 http://www.biomedcentral.com/1472-6947/1/6
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cutaneous biopsy for diagnosis of cirrhosis was obtained
[23].
Data extraction
Primary data abstracted from included studies by one au-
thor (GdB). The data was arranged in 2 ×  2 contingency ta-
bles with participants classified according to the presence
or absence of a physical sign, given the presence or ab-
sence of cirrhosis as defined by liver biopsy. Qualitative
and quantitative study characteristics regarding validity,
clinical description of the study population, description
of the examination methods, and applicability, were ex-
tracted onto data forms.
Calculation of summary statistics
Primary study data for each physical finding was analyzed
using a computer program, Meta-Test version 0.6 (J Lau,
New England Medical Center, Boston 1997). The meta-
analytic approach followed the recommendations of Mid-
gette et al[27] and are similar to methods outlined in a re-
cent review [28]. The correlation between sensitivity and
(1-specificity) was tested using Spearman's rank correla-
tion coefficient. Where sensitivity and (1-specificity) were
significantly correlated (Spearman's ρ  > 0.5), a Summary
Receiver Operating Characteristic (SROC) curve was used
to summarize the data. Where the correlation between
sensitivity and (1-specificity) was <0.5 or negative, homo-
geneity of sensitivity and specificity was tested by chi-
square tests of association. If sensitivity and specificity
were both homogeneous, a summary estimate of sensitiv-
ity and specificity were independently derived using a ran-
dom-effects model (REM). If the sensitivity and specificity
were heterogeneous, no summary estimate was derived.
The SROC curves were created using the method de-
scribed by Moses et al[29,30]. The SROC curve depicts the
trade-off between sensitivity and specificity across differ-
ent studies with explicit or implicit variation in test
threshold. Unweighted regression analyses were exam-
ined to determine the SROC curve. Symmetry of the SROC
curve was confirmed by determining whether the slope of
the fitted regression line differed significantly from zero.
The point of maximum joint sensitivity and specificity
was determined from the curve, as an overall summary
measure. In some instances, the SROC curve did not ex-
tend to a point where sensitivity is equal to specificity. In
those instances, the REM summary estimates were used to
describe the data. Statistical significance was assigned to a
P-value less than 0.05.
Subgroup analyses
Where a minimum of three studies per subgroup were
present, subgroup analyses were planned to determine the
effects of covariates on estimates of diagnostic accuracy.
Covariates postulated to be of possible significance were:
study size (<100 vs. ≥  100), independence of examination
and reference standard (4 point scale – 1 = test measured
independent of reference standard, and reference stand-
ard measured independent of test, 2 = test measured inde-
pendent of reference but not vice versa, 3 = reference
standard measured independent of test, but not vice versa,
4 = neither test nor reference standard measured inde-
pendently of each other), study design (prospective, retro-
spective, or experimental), and primary etiology of
cirrhosis in the study population (alcohol, viral hepatitis,
or other). Residuals of the unweighted regression line de-
scribing the SROC curve were grouped by the covariate of
interest. Student's t-test was used to compare the sub-
groups [29,31].
Results
Results of literature search
The trial flow is presented in Figure 1. The literature
searches identified 3451 citations. Of these, 44 titles ap-
peared relevant and were retrieved. Thirteen articles [32–
44] of potential significance were selected for review. A
further 16 articles [13,22,24,45–57] were found through
hand searching bibliographic references. Twelve articles
[37,38,40,41,44–47,49,51,53,57] met inclusion criteria.
Of the 17 studies excluded, eight studies did not report
data for physical signs, two enrolled only cirrhotic pa-
tients, five studies did not include sufficient data to calcu-
late summary measures of diagnostic accuracy, and one
was a review article. Two studies grouped data for patients
with cirrhosis together with data for patients with other
histological lesions.
Study characteristics
Details of clinical characteristics of the study population
for each included study are presented in Additional Table
(see Additional file 1: Additional Table). Included studies
enrolled a total of 1895 patients. Patients ranged in age
from 3 to 90 years. The ten studies that reported gender
composition included 1168 males (65%) and 628 fe-
males (37%). The median study size was 101 patients,
with an interquartile range of 59 to 229. Most of the in-
cluded studies took place in referral populations (n = 10).
Detection of persistent elevation of aminotransferase lev-
els was the most frequent eligibility criterion for study en-
try (n = 5). Five studies reported an estimated duration of
illness, which varied from a total duration of illness of less
than six months to a mean of 30 months. Comorbid ill-
ness was mentioned in one study [38] that enrolled pa-
tients with inherited coagulation disorders, usually
hemophilia. Fifteen of these patients (44%) were also in-
fected with the Human Immunodeficiency Virus (HIV).
The principal causes of liver disease, as reported in each
included study, are presented in Table 1. Three studies
mainly enrolled patients with chronic viral hepatitis
[38,40,44], four mainly with alcohol- related liver diseaseBMC Medical Informatics and Decision Making 2001, 1 http://www.biomedcentral.com/1472-6947/1/6
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[37,49,51,53], and one with predominantly autoimmune
hepatitis [47]. The remainder reported a presumed etiolo-
gy for less than 50% of the study population.
Aspects of study design and validity are presented in Table
2. Details regarding the expertise of the clinician perform-
ing the biopsy were not provided in any of the studies.
However, it is reasonable to infer that the biopsy was per-
formed by expert clinicians in at least ten of the studies,
namely those that originated in referral centers. Eleven of
twelve studies reported that either the clinical examina-
tion was performed prior to the biopsy and that blinded
pathologists read the biopsy, or that at least the examina-
tion was performed prior to the biopsy. It was generally
not stated how many examiners reviewed the biopsies (n
= 7). The reliability of the pathological diagnosis was as-
sessed in a single study [57]. These investigators reported
that biopsies were examined by two experienced patholo-
gists. Good agreement beyond chance (κ  = 0.67) was
present for the pathological diagnoses in this study. Three
other studies stated that a single examiner reviewed the
slides [46,47,51] and one stated that experience patholo-
gists reviewed the slides [45].
In nine studies, the biopsy was performed irrespective of
the findings on clinical examination. In the case-control
study [44], the control group did not undergo liver biop-
sy. In two studies [38,49], it was not clear whether the de-
cision to perform the biopsy was taken independently of
clinical data. Five studies reported on exclusions
[37,38,40,53,57]. These ranged from 12.7% (44 of 347)
to 39.3% (22 of 56). Common reasons for exclusion were:
the presence of contraindications to biopsy, the patient
did not undergo biopsy, or inadequate biopsy.
In all studies, examiners were not blinded to other clinical
information. In some cases, the entire history and exami-
nation was performed together. In other cases, multiple
physical signs were evaluated. Only two studies gave any
details regarding the specific clinical methods used
[44,46], and four mentioned the explicit threshold for ab-
normality of a clinical finding [44,46,51,57]. Five studies
did not state how many examiners assessed each patient,
four studies reported that a single examiner was used, and
three studies used two examiners to evaluate physical
signs. Reliability was assessed in four studies
[41,44,46,57], although results were only provided in one
study [57], and for only three clinical indicants. These in-
vestigators found good agreement beyond chance for liver
firmness (κ  = 0.72), spleen size (κ  = 0.66), and stated that
agreement for liver enlargement was similar (κ  not stat-
ed).
Accuracy of history and physical examination
Ten physical signs or findings were reported in three of
more studies. SROC curves were constructed for splenom-
egaly and hepatomegaly (Figures 2 and 3). The data for as-
cites were unsuitable for SROC analysis, and so were
combined using summary measures from a REM. The
maximum joint sensitivity and specificity of the finding of
splenomegaly was 0.64, and 0.75 for hepatomegaly.
A sensitivity analysis was performed to evaluate the effect
of inclusion of those studies most liable to various types
of bias. When the case-control study [44] was excluded
from the analysis of the hepatomegaly data, the SROC
curve was essentially unchanged. A joint maximum sensi-
tivity and specificity for the revised hepatomegaly SROC
curve was 0.75 (data not shown). By comparison, exclu-
sion of the study in which clinical and pathological assess-
ments were not independent [45] from the splenomegaly
dataset resulted in a dramatic change. The SROC curve for
this data was greatly influenced by the presence of this
outlying point. Random-effects estimates for the revised
splenomegaly data of sensitivity were 0.82 (95% CI: 0.52
– 0.95) and specificity 0.60 (95% CI: 0.21 – 0.89).
Data on seven physical signs were combined using sum-
mary measures derived from a REM, as shown in Table 3.
The data for palmar erythema was heterogeneous and un-
suitable for meta-analysis. Reported sensitivity ranged
Figure 1
Trial Flow Of Studies.BMC Medical Informatics and Decision Making 2001, 1 http://www.biomedcentral.com/1472-6947/1/6
Page 5 of 11
(page number not for citation purposes)
from 0.12 to 0.63 and specificity ranged from 0.49 to
0.98. A further ten physical signs were evaluated in single
studies. The diagnostic accuracy for these findings is rep-
resented in Table 4.
Subgroup analyses of SROC analyses
Subgroup analyses were possible for splenomegaly and
ascites. None of the covariates examined, namely: study
size, study design, etiology of cirrhosis, and independence
of measurements, resulted in a significant difference in di-
agnostic performance of the physical sign in question.
There was significant heterogeneity of TPR and TNR in the
subgroup of studies reporting splenomegaly that had as-
sessed biopsy findings with knowledge of the clinical
findings.
Discussion
The present study attempted to summarize data from pri-
mary sources in the published medical literature on the
diagnostic accuracy of clinical findings for the diagnosis of
cirrhosis. The studies identified represent a rather select
population. Studies were primarily conducted in referral
centers, by clinicians experienced in dealing with liver dis-
ease, seeing patients with increased clinical suspicion of
the disorder of interest. The underlying etiology of liver
disease was not comprehensively reported, and in several
Table 1: Principal etiology of liver disease for patients enrolled to included studies, according to study classification
FIRST AUTHOR ALCOHOL (%) CHRONIC VIRAL HEPATITIS (%) AUTOIMMUNE (%) CRYPTOGENIC (%)
Schenker 64 - - -
Nakamura 100 - - -
Rankin 100 - - -
Cozzolino - 20† - -
Hay CRM - 71‡ - -
Lashner - 58 - 42
Hay JE - - 53 47*
Tinè 9 15† - -
Marmo 25 23† - -
Zoli 21 53 12 11
Hamberg 100 1 - -
*21% possibly non-alcoholic steatohepatitis (NASH) † Hepatitis B surface antigen positive ‡ Classified as non-A, non-B hepatitis
Table 2: Design and validity criteria of twelve studies that met entry criteria
FIRST AUTHOR YEARS OF STUDY 
ENROLLMENT
N DESIGN INDEPENDANCE OF 
MEASUREMENTS*
APPLICATION OF BIOPSY
Schenker 1958–1959 61 Prospective 2 All
Nakamura 1951–1961 52 Retrospective 2 All
Rankin NS 100 Prospective 1 All
Czaja NS 101 Prospective 1 All
Cozzolino NS 213 Retrospective 4 All
Hay CRM 1977–1986 35 Retrospective 2 All
Lashner 1977–1981 94 Retrospective 1 All
Hay JE 1984–1987 47 Prospective 1 All
Tinè 1984–1985 277 Prospective 1 All
Marmo 1986–1990 412 Retrospective 2 All
Zoli NS 200 Case-control 2 Control patients not biopsied
Hamberg 1968–1971 303 Prospective 2 All
*1, test measured independant of reference standard, and reference standard measured independant of test, 2, test measured independant of refer-
ence but not vice versa, 3, reference standard measured independant of test, but not vice versa, 4, neither test nor reference standard measured 
independantly of each other. NS, not stated.BMC Medical Informatics and Decision Making 2001, 1 http://www.biomedcentral.com/1472-6947/1/6
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studies, no description of the patient population was giv-
en. Few studies described their clinical methods, where
several exist for eliciting a finding [58–60]. These are defi-
ciencies that should be carefully addressed in designing
future studies that evaluate aspects of clinical practice,
such as the history or physical examination. These defi-
ciencies are a phenomenon that is not restricted to studies
of clinical evaluation of liver disease, adding support to
the call for more rigorous studies of the clinical examina-
tion [61].
The summary measures derived from the data presented
here demonstrate that the physical findings elicited in the
primary studies have high specificity, though generally
low sensitivity, for detecting cirrhosis. As expected, physi-
cal signs consistent with advance portal hypertension or
severe liver dysfunction (decompensated cirrhosis), like
ascites, abdominal wall veins (collateral circulation), or
encephalopathy, had high specificity of over 90%. There
was significant heterogeneity in the reported diagnostic
accuracy of palmar erythema, precluding meta-analysis.
In the case of the physical signs splenomegaly and
hepatomegaly, studies indicated the presence of a varia-
tion in test threshold, as an explanation for the variation
in test accuracy. In the case of splenomegaly, however, this
finding was sensitive to the inclusion of one study with
potential for bias of the diagnostic accuracy of clinical
evaluation.
Subgroup analyses were not able to detect variation in ac-
curacy as a consequence of study characteristics. The small
number of studies available conferred low power to detect
such differences. Data were insufficient to examine other
study characteristics that may have influenced study out-
come, such as age of participants, cause of liver disease, or
symptom duration. Increases in age or duration of illness
may bias studies towards higher prevalence of cirrhosis.
The present study employed a comprehensive search strat-
egy. Formal criteria for study inclusion were defined prior
to analysis of the search results. We were unable to find
previous attempts to summarize the accuracy of clinical
examination for diagnosis of cirrhosis in the medical liter-
ature. Our results agree however, with comparisons span-
ning five decades of the antemortum clinical diagnosis
with subsequent autopsy studies [62].
This study has several limitations. Firstly, a question re-
mains on the choice of diagnostic reference standard. Liv-
er biopsy is likely to underestimate the actual prevalence
of cirrhosis [50]. Methods to overcome this limitation in-
clude examining multiple biopsies. One study required
three successive negative biopsies to exclude the diagnosis
of cirrhosis [46]. Although this approach addresses the
concern of sampling variability, it is questionable whether
it could be considered in future studies using biopsy as the
gold standard, as it may not be ethically defensible. This
remains an area for improvement in future studies, and
consensus on standardization.
Misclassification of patients by an imperfect reference test
will lead to bias in the assessment of a diagnostic test
[63,64]. In general, an imperfect reference test will under-
estimate the performance of a diagnostic test. Sample cal-
culations to show how such errors in a reference test lead
to alterations in the apparent sensitivity and specificity of
a diagnostic test are presented in Appendix 1 and 2 (see
Additional file 2: Appendices). These calculations are
based on methods developed by Gart and Buck [65]. As
can be seen, a diagnostic test with true sensitivity of 0.9
would appear to have a sensitivity of only 0.612 if the ref-
erence standard against which it was measured had an im-
perfect sensitivity and specificity of 0.8 and 0.95,
respectively. Meta-analytic methods have been described
to adjust for imperfections in the reference standard, al-
Figure 2
Summary receiver operating characteristic curve of the diag-
nostic accuracy of splenomegaly in the diagnosis of histologi-
cally-proven cirrhosis. Numbers refer to studies: 1 =
Schenker [53], 2 = Czaja [46], 3 = Cozzolino [45], 4 = Hay
CRM [38], 5= Lashner [40], 6 = Hay JE [47], 7 = Tinè [57], 8
= Marmo [41], 9 = Nakamura [49], 10 = Rankin [51]. Light
gray box depicts point estimate (cross) with 95% confidence
limits for random effects model estimates of sensitivity and
specificity. Dark gray box depicts fixed effects model point
estimates and confidence limits of estimates of sensitivity and
specificity.
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though those techniques were not applied to the data pre-
sented here [66].
Secondly, it is likely that other types of bias were present
in some of these studies. Empirical observation of the
quantitative effects of study design flaws on the findings
of diagnostic studies has shown that case-control designs,
studies that use different reference tests for positive and
negative results of the diagnostic test under study, and
lack of blinding led to overestimation of diagnostic test
accuracy [67]. One case-control study was retrieved in the
searches [44]. No important difference was noted in the
hepatomegaly SROC curve, whether this particular study
was included or not. One retrospective study appeared to
have a significant risk of bias from lack of blinding [45].
The exclusion of this study from the splenomegaly SROC
significantly altered the analysis of this data, showing the
vulnerability of the meta-analysis to this form of study bi-
as.
Several other forms of bias have not been shown to be im-
portant predictors of variation in assessment of diagnostic
accuracy [67]. Selection bias refers to the bias that may re-
sult if not all patients with the condition under study are
consecutively included. Such a bias may have influenced
the results of at least one study (reference 42). Verification
bias refers to the bias that may occur if the reference test is
applied based on the results of the diagnostic test being
studied. Several studies were described as having exclu-
sions, which raised the possibility of selective application
of the gold standard. Statistical methods for evaluating di-
agnostic test performance in the presence of such partial
verification have been described, but require the applica-
tion of a second initial diagnostic test [68]. Consequently,
such an approach was not used in this paper.
Thirdly, the data obtained were insufficient to assess the
effect of study location on diagnostic accuracy. The de-
crease in specificity of physical signs as patients are re-
ferred from primary to tertiary care settings, in which most
of these studies were performed, has been described [61].
As most of the studies utilized persistently elevated ami-
notransferase levels as eligibility criteria, rather than the
physical signs under study, no data are available to evalu-
ate whether over- or underrecognition by the referring cli-
nicians led to an altered specificity in results of the cited
article.
Fourth, the available data did not allow an analysis of
how individual patient characteristics affect diagnostic ac-
curacy of physical findings. It has been observed that cir-
rhosis undetected during life was a finding typical of
elderly patients [69]. Similarly, the prevalence of certain
physical findings, or alternatively the ability to detect
those signs, may vary between patients of different race
[70].
Fifth, this study cannot assess the independence of isolat-
ed clinical findings. The role and diagnostic accuracy of
items from the clinical history were not examined. It is
likely that some of the study clinicians were aware of indi-
cants from the clinical history. Whether these elements of
the evaluation made clinicians examine patients more in-
tensively than those with a negative history is unknown.
The possibility also exists that finding one physical sign
may have heightened attempts by examining clinicians to
elicit further signs. If clinicians utilized additional maneu-
vers, hence deviating from their usual course of clinical ex-
amination, on the strength of finding other more easily
elicited signs, the study results may have become biased.
The appropriateness of examining an isolated clinical sign
may also be challenged [61].
Sixth, data from the primary studies are limited on the
specific clinical maneuvers used to derive the estimates of
diagnostic accuracy. Thus, the findings cannot be related
to the accuracy of a specific clinical approach.
Figure 3
Summary receiver operating characteristic curve of the diag-
nostic accuracy of hepatomegaly in the diagnosis of histologi-
cally-proven cirrhosis. Numbers refer to studies: 1 =
Schenker [53], 2 = Marmo [41], 3 = Zoli [44], 4 = Hamberg
[37], 5 = Nakamura [49], 6 = Rankin [51]. Light gray box
depicts point estimate (cross) with 95% confidence limits for
random effects model estimates of sensitivity and specificity.
Dark gray box depicts fixed effects model point estimates
and confidence limits of estimates of sensitivity and specifi-
city.
1 - Specificity
S
e
n
s
i
t
i
v
i
t
y
  0
  0
 10
 10
 20
 20
 30
 30
 40
 40
 50
 50
 60
 60
 70
 70
 80
 80
 90
 90
100
100
1
2
3
4
5 6BMC Medical Informatics and Decision Making 2001, 1 http://www.biomedcentral.com/1472-6947/1/6
Page 8 of 11
(page number not for citation purposes)
This study may have implications for how clinicians per-
form and interpret their clinical examination findings.
Perloff recently drew attention to the ongoing importance
of skillful clinical evaluation in cardiovascular disease
[71]. These data show that in patients with cirrhosis, indi-
vidual clinical signs usually have low sensitivity, with high
specificity. Thus, physical signs cannot be used to exclude
the diagnosis of cirrhosis, given these performance charac-
teristics. Signs are likely to be more useful to clinicians in
the discrimination of patients with disease by identifying
patients with a higher likelihood of cirrhosis, thereby "rul-
ing-in" the diagnosis [25]. The main obstacle to the timely
use of such an approach is the finding that signs with the
highest specificity are those present in decompensated
disease.
This study has implications for clinical research. This
study has highlighted the selected nature of existing data
on diagnostic accuracy of clinical examination and meas-
urement parameters for cirrhosis. Attempts to further de-
fine diagnostic accuracy of clinical examination will have
to consider how to define and measure independently the
contribution of individual covariates or physical signs,
and which combination of cofactors has the highest sen-
sitivity, specificity, or positive predictive value. A poten-
tially useful consideration would be the gain in sensitivity
and specificity that might result from using a combination
of signs. Further attention should be devoted to finding
ways to identify patients with cirrhosis. Non-invasive lab-
oratory testing such as serologic or molecular markers, im-
aging studies, or improved biopsy techniques appear to be
the principal avenues open to innovation in this area.
Conclusions
1. Most studies examining the diagnostic accuracy of clin-
ical examination have been undertaken in highly selected
populations.
2. Physical signs are generally of low sensitivity for the di-
agnosis of cirrhosis, and signs with higher specificity are
associated with clinically decompensated disease, thus no
rules of generality can be deduced.
3. Physical signs are not useful for excluding the presence
of cirrhosis, but may be useful to indicate the presence of
cirrhosis in a person with moderate to high pretest suspi-
Table 3: Summary diagnostic accuracy derived from random-effects models
FINDING STUDIES SENSITIVITY 95%Cl SPECIFICITY 95% Cl
Ascites 7 0.34 0.22–0.49. 0.95 0.89–0.98
Collateral circulation 3 0.42 0.26–0.61 0.94 0.71–0.99
Encephalopathy 3 0.15 0.06–0.33 0.98 0.97–0.99
Firm liver 3 0.68 0.55–0.79 0.75 0.62–0.85
Jaundice 3 0.36 0.25–0.48 0.85 0.80–0.89
Spider angiomata 8 0.50 0.39–0.61 0.88 0.75–0.95
Table 4: Sensitivity and specificity of selected physical findings reported in a single study.
FINDING FIRST AUTHOR SENSITIVITY 95%Cl SPECIFICITY 95%Cl
Facial telangectasia Hamberg 0.82 0.68–0.91 0.92 0.88–0.95
Gynaecomastia Hamberg 0.18 0.09–0.32 0.97 0.94–0.99
Irregular liver surface Marmo 0.52 0.46–0.58 0.93 0.87–0.97
Parotidomegaly Schenker 0.13 0.04–0.32 1.00 0.89–1.00
Peripheral edema Hamberg 0.24 0.14–0.39 0.91 0.87–0.94
Sharp liver edge Zoli 0.49 0.37–0.60 0.21 0.11–0.36
Tender liver Schenker 0.33 0.18–0.53 0.65 0.45–0.80
Testicular atrophy Hamberg 0.18 0.09–0.32 0.97 0.94–0.99
Thick liver edge Zoli 0.51 0.40–0.63 0.79 0.64–0.89
White nails Hamberg 0.43 0.29–0.58 0.98 0.95–0.99BMC Medical Informatics and Decision Making 2001, 1 http://www.biomedcentral.com/1472-6947/1/6
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cion of disease. Physical signs need to be utilized with ad-
ditional clinical criteria to augment the probability of
identifying patients with cirrhosis.
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